Please login to the form below

Not currently logged in
Email:
Password:

vedolizumab

This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.

Biologics set to revolutionise the gastrointestinal market

Biologics set to revolutionise the gastrointestinal market

Also contributing to the predicted market growth are recent product approvals such as Takeda's Takecab (vonoprazan) for gastroesophageal reflux disease, and Entvio (vedolizumab) for IBD.

Latest news

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Marketing Tree
Channeling your inner disrupter
Channel strategy has long been a hot topic for pharma and is often regarded as the answer to many of today's marketing challenges...
Influencing behaviour change: Looking beyond market research
These strategies will give you the insight you need to influence behaviour change by creating a meaningful pharma customer journey....
Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...

Infographics